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Abstract
Background: Gene profiling of diffuse large B cell lymphoma (DLBCL) has revealed broad gene expression
deregulation compared to normal B cells. While many studies have interrogated well known and annotated genes
in DLBCL, none have yet performed a systematic analysis to uncover novel unannotated long non-coding RNAs
(lncRNA) in DLBCL. In this study we sought to uncover these lncRNAs by examining RNA-seq data from primary
DLBCL tumors and performed supporting analysis to identify potential role of these lncRNAs in DLBCL.
Methods: We performed a systematic analysis of novel lncRNAs from the poly-adenylated transcriptome of 116
primary DLBCL samples. RNA-seq data were processed using de novo transcript assembly pipeline to discover novel
lncRNAs in DLBCL. Systematic functional, mutational, cross-species, and co-expression analyses using numerous
bioinformatics tools and statistical analysis were performed to characterize these novel lncRNAs.
Results: We identified 2,632 novel, multi-exonic lncRNAs expressed in more than one tumor, two-thirds of which are
not expressed in normal B cells. Long read single molecule sequencing supports the splicing structure of many of these
lncRNAs. More than one-third of novel lncRNAs are differentially expressed between the two major DLBCL subtypes, ABC
and GCB. Novel lncRNAs are enriched at DLBCL super-enhancers, with a fraction of them conserved between human and
dog lymphomas. We see transposable elements (TE) overlap in the exonic regions; particularly significant in the last exon
of the novel lncRNAs suggest potential usage of cryptic TE polyadenylation signals. We identified highly co-expressed
protein coding genes for at least 88 % of the novel lncRNAs. Functional enrichment analysis of co-expressed genes
predicts a potential function for about half of novel lncRNAs. Finally, systematic structural analysis of candidate point
mutations (SNVs) suggests that such mutations frequently stabilize lncRNA structures instead of destabilizing them.
Conclusions: Discovery of these 2,632 novel lncRNAs in DLBCL significantly expands the lymphoma transcriptome and
our analysis identifies potential roles of these lncRNAs in lymphomagenesis and/or tumor maintenance. For further
studies, these novel lncRNAs also provide an abundant source of new targets for antisense oligonucleotide
pharmacology, including shared targets between human and dog lymphomas.
Background
Gene expression profiling of diffuse large B cell lymphoma
(DLBCL) has revealed broad gene expression deregulation
compared to normal B cells. These studies identified two
main DLBCL subtypes - activated B-cell like (ABC) and
germinal center B-cell (GCB) – associated with distinct
clinical outcomes [1]. They also identified involvement of
other signatures, for example, a stromal signature [2].
These studies used microarray to measure gene expression
and therefore only interrogated well-known and annotated
genes. Additional recent studies used transcriptome se-
quencing (RNA-seq) to look for gene fusions and deregu-
lated pathways in DLBCL [3].
In theory, RNA-seq data can be examined to look for
novel, yet unannotated, transcripts. While it is generally
thought that most of the proteins coding genes encoded
in the human genome have been discovered, many yet
unannotated long non-coding RNAs (lncRNAs) are
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thought to exist. LncRNAs are a type of ncRNA that are
at least 200 bp long and are spread across the intergenic
regions in the genome. Based on recent studies, some of
these lncRNAs, despite being non-coding, are shown to
play critical roles in disease specific epigenetic gene regu-
lation, including in cancer biology [4]. For example, sev-
eral lncRNAs interact with the Polycomb complex (PRC1/
PRC2) to promote repression of gene expression [5, 6].
The discovery of novel lncRNAs is challenging for a
number of reasons, including their frequent low expres-
sion, the algorithmic and statistical complexity of de
novo discovery. Nonetheless, these challenges are being
overcome and several groups have performed systematic
analysis of lncRNAs in normal cells and also in primary
tumors. A recent cross-cancer study by the Chinnaiyan
group uncovered thousands of novel lncRNAs [7]. An-
other study by the Maher group identified a large num-
ber of novel lncRNAs in lung cancer [8].
In the present study, we sought to discover and
characterize novel lncRNAs in DLBCL using a de novo
transcript discovery strategy based on RNAseq of primary
DLBCLs and normal B cell samples. We performed a sys-
tematic analysis of 116 tumors and used stringent filtering
based on conventional characteristics of lncRNAs in terms
of coding properties, length, exon counts, and expression
levels to identify high-confidence novel lncRNAs. We iden-
tified a total of 2,632 novel DLBCL lncRNAs. Subse-
quently, we applied a broad range of analyses to these
lncRNAs to further understand their function. For ex-
ample, we looked for lncRNAs co-expressed with PRC2
components such as EZH2 to identify potential PRC2
interaction partners. We analyzed the network of co-
expressed protein coding genes to identify a potential func-
tion for each lncRNA. We inspected the local genomic
neighborhood of lncRNAs to look for functional enrich-
ment. We analyzed the correlation between lncRNAs and
disease features such as tumor subtypes (ABC vs. GCB),
DLBCL super-enhancers and how mutations in lncRNAs
may impact their function. For the first time, a cross-
species analysis of lncRNAs was performed and we found
that a non-negligible fraction of human DLBCL lncRNAs
is also expressed in canine lymphoma. We also identified
novel features of lncRNAs, such as their significant overlap
with transposable elements, especially within the last exon.
Altogether, these analyses strongly suggest that novel
DLBCL lncRNAs are functionally embedded within lymph-
oma gene networks and play important roles in lympho-
magenesis and/or maintenance of the lymphoma
phenotype. At a time where antisense oligonucleotides are
starting to demonstrate clinical potential [9] this study pro-
vides a wealth of potential new anti-lymphoma pharmaco-
logical targets. The conservation of some of these lncRNAs
in dogs suggests a potential route for developing anti-
lymphoma strategies based on dog therapeutic trials.
Methods
Data
Computational analysis was performed on multiple sets of
RNAseq data, including 116 TCGA dbGAP DLBCL tumor
samples (dbGaP accession number phs000235.v6.p1 –
dbGaP approval for this specific project was granted). The
eight normal B-cell (four naïve B cells and four germinal
center B cells) samples were obtained from a previous
study dataset (GEO dataset: GSE45982) and 30 DLBCL
cell lines (Additional file 1) were obtained from the Mel-
nick lab. The naïve B cells (from tonsillar naïve B cells)
and centroblast (from tonsillar germinal center B cells)
were treated by magnetic bead cell separation and the
total RNA was extracted for RNA-seq using Qiagen kits
[33]. Polyadenylated RNA-seq was performed using the
standard Illumina Truseq kits and samples were se-
quenced using HiSeq2000 with one to three samples per
lane. RNA-seq data from dog lymphoma samples were ob-
tained from DNANexus [27] and used for the cross-
species analysis.
RNA-seq and de novo transcript assembly pipeline
All RNA-seq analyses were performed using conven-
tional RNA-seq analysis tools. All RNA-seq short reads
were aligned to human reference genome (version hg19/
GRCh37) using STAR [10]. Post alignment, the aligned
reads were put through de novo transcript assembly and
numerous bioinformatics tools, along with some in-
house scripts for processing.
De novo transcript assembly to obtain novel transcripts
The ab initio transcript assembly was performed using
CuffLinks (v2.2.1) [8] in de novo mode to assemble tran-
scripts for 116 DLBCL tumor samples and eight normal
B cell samples. The assembled transcript fragments from
the cohort of tumor and normal B cell samples, were
merged to create a consensus transcriptome GTF file,
using the tool CuffMerge [8]. This consensus transcrip-
tome was parsed to filter out any previously annotated
transcripts such as known protein coding genes and
known lncRNAs. A consensus dataset of known annota-
tions was created using protein coding gene annotations
from UCSC, GencodeV17, RefSeq, and Ensembl, while
known lncRNA annotations were obtained from Human
lncRNA catalog-Broad institute. Using the tool Cuff-
Compare, the assembled consensus transcriptome GTF
was compared to the database of known annotations to
obtain a consensus novel transcript GTF for further
analysis.
Filtering for novel lncRNA candidates
Stringent filtering was performed to control for artefac-
tual and other background noise generated due to de
novo assembly of the alignments, which may have been
Verma et al. Genome Medicine  (2015) 7:110 Page 2 of 17
counted in as a novel transcript. Filtering was done for
coding potential, transcript length, and number of exons.
Coding Potential Assessment Tool (CPAT) [9] was used
to compute the coding potential for each transcript.
Given a FASTA input, CPAT uses logical regression
model based on ORF size, Fickett score, and hexamer
usage bias. Based on these, CPAT predicts each tran-
script’s coding property and assigns a coding potential
score in the range of 0–1, with CPAT score <0.364
assigned for non-coding transcripts and >0.364 for
protein-coding transcripts. The length of each non-
coding transcript was also obtained from the results of
CPAT, which was used in filtering for transcript length,
selecting long sequences (> = 200 bp). An in-house script
was used to count the number of exon per transcript
from the assembled unannotated transcripts GTF and
those with at least 2 exons or more were included for
analysis. A final novel lncRNA GTF was then created
with the filtered in transcript fragments. Using the novel
lncRNA GTF as reference, novel lncRNA candidates
were quantified for FPKM levels in all samples in
DLBCL tumor, normal B cells, and DLBCL cell lines,
using CuffLinks. Based on the obtained FPKM levels,
each lncRNA expressed in at least two or more samples
were established as the selected novel lncRNA candi-
dates and used for all further analysis.
Divergently transcribed lncRNAs
LncRNAs transcribed in an opposite orientation from
the identified nearest protein-coding gene. These diver-
gently transcribed lncRNAs were selected based on a
two-step analysis. First, all lncRNAs whose first exons
were within 2 kb of a protein-coding gene were selected.
Then out of these, those which were transcribed in the
antisense orientation from their nearest protein-coding
gene were selected as divergently transcribed lncRNAs.
Statistical analysis
Almost all of the statistical analysis for correlations, dif-
ferential expression, and other statistical tests applied
were performed using R statistical analysis software.
Controls for false positives and significance stringency
were applied accordingly based on each analysis. FPKM
based differential expression analysis per lncRNA was
performed on ABC and GCB classified samples using t
test statistic. Multiple hypotheses testing correction was
then performed on significantly differentially expressed
lncRNA across ABC and GCB by adjusting for P values.
Only transcripts differentially expressed across the sub-
types with adjusted P value (FDR) <0.05 were considered.
Repeat elements analysis
Transposable element reference used for comparison
was first filtered to remove low complexity and satellite
repeats, to focus on the major transposable elements sub
families. BEDtools (v2.23.0 ) [11] intersect was used to
obtain the exonic overlap between novel lncRNAs and
transposable elements. Partial or complete exonic over-
laps were only considered as valid overlaps. Another
tool, RepeatMasker [12], was used to obtain sequence
based overlap of TE with novel lncRNA for lncRNAs,
giving the TE-derived percentage. Dividing the base-by-
base TE overlap for a transcript by the total length of
that transcript returned the TE-derived percentage. All
transcripts, which showed some percentage of sequence
based overlap with TE, were termed as TE-derived.
Cross-species analysis
Dog transcriptome was reconstructed, using CuffLinks
in de novo mode post alignment to CanFam3 genome
build. This reconstruction was then filtered to obtain
multiexonic transcripts using an in-house script. For a
consistent comparative analysis, the tool LiftOver was
used to convert genomic coordinates in BED format
from human to canine, using the UCSC [13] chain file
for hg19toCanFam3 as reference. Lifted over human
lncRNAs were then intersected with the Dog transcripts
using BEDtools intersect.
Mutation analysis
SNVs in the exonic regions of the novel lncRNAs were
identified using VarScan (minimal coverage of 8 and
variant allele frequency of 0.2), based on the samtools
generated pileup input format of the lncRNA regions.
All SNVs present in the intronic regions were removed
using BEDtools intersect. SnpSift from snpEff toolbox
[14] was then used to remove the already annotated
SNVs using the dbSNP annotations as reference, to ob-
tain only novel mutations (SNVs). These novel SNVs
were then used to create a mutated human genome ref-
erence using the GATK tool FastaAlternateReference-
Maker [15]. Based on the VCF with exonic mutations,
this tool mutated the original reference, which was then
used to create mutated lncRNA FASTA sequences. The
program gffread, included in the CuffLinks package, was
used to generate all FASTA sequences, given a GTF and
corresponding genome reference.
Given the FASTA sequence for the native sequences
of the lncRNAs and the mutated sequence of the
lncRNAs, RNAfold was then used to compute the mini-
mum free energy (MFE) of the secondary RNA struc-
ture in unit kcal/mol. A difference in the original/
wildtype MFE and mutated MFE of each lncRNA tran-
script was then used to study the shift in the energies.
Similar analysis was carried out for the exonic dbSNP
mutations present in the lncRNAs, as a control for the
study in the change of MFE.
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Visualization
Integrative Genomics Viewer (IGV browser v.2.3.34)
[16] was used to visualize and document the genomic
coordinates in various file formats.
Results
De novo transcript discovery identifies 2,632 novel
lncRNA in DLBCL tumors
We hypothesized that de novo analysis of primary DLBCL
RNAseq would help uncover novel lncRNAs. RNA-Seq
reads from a cohort of 116 primary DLBCL tumor sam-
ples (dbGaP accession number phs000235.v6.p1) were
aligned to human reference using an RNA-seq aligner
(STAR) and were then subjected to ab initio transcript as-
sembly [17]. We also processed eight normal B cell RNA-
seq samples (four naïve B cells and four germinal center B
cells) using the same analysis. The initial transcript sets
were merged and only those transcripts that do not over-
lap any previously annotated protein-coding gene or
known lncRNAs according to annotations from known
gene databases (UCSC, GencodeV17, RefSeq, Ensembl,
Human lncRNA catalog-Broad institute) were retained
(Fig. 1a). This set of novel candidate lncRNAs was put
through further stringent filtering based on established
properties of a lncRNA, including coding potential, tran-
script length, and exon numbers, to obtain a specifically
characterized group of lncRNAs (Fig. 1b). Novel candidate
lncRNAs were first checked for coding potential to deter-
mine if they held coding properties, using CPAT [18].
LncRNAs which passed the CPAT coding potential score
cutoff (<0.364) for non-coding genes, were selected for
further analysis. Out of the non-coding transcripts, we se-
lected transcripts with length of 200 bp or greater. Since it
is possible that de novo assembly may have improperly as-
sembled artefactual background noise, un-spliced pre-
mRNA or gene extensions, only multiexonic transcripts
were selected for further analysis. After applying these
stringent filters, we were left with 2,913 novel DLBCL/
normal B cell lncRNAs. We quantified the expression
levels of these 2,913 lncRNAs in all tumors and all normal
B cell samples and only retained lncRNAs that have ex-
pression (FPKM >0.1) in at least two or more samples in
each of the sample groups. The FPKM threshold was
chosen after analyzing the known lncRNAs, which show
comparable levels of expression and other previously pub-
lished lncRNA analysis in other cancers which also used
FPKM cutoff of <0.1 [7, 8]. This analysis led to 2,632
lncRNAs expressed in tumors and 941 lncRNAs expressed
in normal B cell samples (Fig. 1b). All further analyses
below were performed on the 2,632 tumor-expressed
lncRNAs (Additional file 2).
Coding potential scores for the 2,632 novel lncRNAs,
known lncRNAs, and protein-coding genes were gener-
ated using GENEID [19] for cross-validation. This
showed novel lncRNAs to emulate the low average cod-
ing potential score of the known lncRNAs in compari-
son to the higher average coding potential score
characterizing the protein coding genes (Fig. 1c). We
also verified that our novel lncRNAs follow similar
length density distribution of known lncRNAs (even
though they tend to be longer) and are on average
shorter than protein-coding genes (t-test, P <2.2e-16)
(Fig. 1d). Finally, we compared the number of exons of
our lncRNAs with the numbers for known lncRNAs and
protein-coding genes: the novel lncRNAs emulate
known lncRNAs, with the majority of them between 2
and 4 exons, while protein-coding genes have a much
larger exon count (Fig. 1e). When we counted how many
lncRNAs are expressed in each tumor, we found that
many lncRNAs were expressed in a few tumors while a
smaller number were expressed across a large number of
tumors (Fig. 1f ). When we compared our 2,632 novel
lncRNAs with those uncovered by Iyer et al. [7] in 27
tissues and cancer types but not in B cell lymphomas,
we only found 17 % overlap suggesting that the vast ma-
jority of our DLBCL novel lncRNAs are DLBCL specific
(Additional file 3: Figure S1).
Many of the novel DLBCL lncRNAs are tumor-specific
We further sought to subdivide the 2,632 tumor-
expressed lncRNAs based on their expression in normal
B cells and DLBCL cell lines. In the latter case, we quan-
tified expression levels of the 2,632 lncRNAs in a panel
of 30 DLBCL cell lines. As before, a lncRNA was consid-
ered expressed if at least two samples within the cell line
group had expression >0.1. Altogether, we found that 763
lncRNAs are expressed in tumors and cell lines but not in
normal B cells. Across the normal B cell subtypes – we
found that 718 lncRNAs of the 2,632 novel lncRNAs are
expressed in centroblasts (FPKM >0.1 in two or more
samples) and 575 in naïve B cells. We also found that only
927 lncRNAs were expressed both in tumors and normal
cells. Out of these 927 lncRNAs, 334 were significantly
differentially expressed across the two normal subtypes –
naïve B Cells and GCB (FDR <0.05) and clustering (super-
vised clustering, using hclust function; method ward)
based on the lncRNAs recapitulated the respective sample
groups (Additional file 4: Figure S2). Another 942
lncRNAs are uniquely expressed in DLBCL tumors, that
is, not in normal B cells or cell lines (Fig. 2a). Finally, 785
lncRNAs were expressed in tumors, cell lines, and normal
B cells and the remaining was expressed in DLBCL tu-
mors and normal B cells but not in cell lines. Comparing
all 2,632 tumor-expressed lncRNAs against normal B cells
(as a single group) showed 1,090 lncRNAs significantly
differentially expressed (FDR <0.05) and clustered across
the sample groups (supervised clustering, using hclust
function in R; method ward), indicating 41 % of these
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Fig. 1 (See legend on next page.)
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differentially expressed lncRNAs across normal and tu-
mors may indeed contribute to lymphomagenesis (Add-
itional file 5: Figure S3).
We analyzed the 785 ubiquitously expressed lncRNAs
and asked how many of them were expressed in each
sample. We found normal samples to have the highest
on average number of expressed lncRNAs per sample,
then tumor samples followed by cells lines which have the
least, respectively (Fig. 2b). This result may suggest that
many lncRNAs are transcriptionally silenced in rapidly
proliferating cells. Alternatively, this result may reflect dif-
ferences in cell type complexity and transcriptional het-
erogeneity between these cell types.
We nonetheless found 45 specific lncRNA that show
exceptionally high expression (> = 10 standard deviation
above mean 2.17 FPKM) in a subset of tumor samples.
Expression levels of one such lncRNA, XLOC_033173, is
shown in Fig. 2c. There were 45 lncRNAs (Additional
file 2) with such pattern of expression across tumor
samples. We speculate that some of these lncRNAs may
be involved in structural alterations that led to their
over-expression [2] and that some of these outlier
lncRNAs may drive these tumors. Indeed, when we over-
lapped these 45 lncRNAs with published data from gen-
ome wide copy number analysis performed in primary
DLBCL tumors [5], using array CGH, we found 33 out
of the 45 lncRNAs overlapped with known recurrently
amplified regions in DLBCL.
Finally, we observed that the 2,632 unique novel
lncRNAs were in fact derived from 4,608 distinct tran-
scripts, indicating presence of multiple isoforms for
some of these lncRNAs. While most of our lncRNAs
have a single isoform, many lncRNAs had more than
one isoform, with the maximum of 23 isoforms for one
of our lncRNAs (Fig. 3a). For example, visualizing some
of these isoforms using sashimi plot (Fig. 3b) and raw
reads (Fig. 3c) for lncRNAs XLOC_003929 across mul-
tiple tumor samples, we observed expression patterns
across clearly defined spliced junctions for various iso-
forms. This suggests that like protein-coding genes,
lncRNAs alternative splicing is used to increase tran-
scriptional (and perhaps functional) complexity.
Integrative analysis reveals potential functions of DLBCL
specific novel lncRNAs
We then reasoned that analyzing our novel lncRNAs in
the context of the genomic and co-expression/network
could help potentially uncover their functions. For ex-
ample, we noticed that a small but significant fraction of
our lncRNAs (n = 166) are transcribed divergently (see
Methods) from nearby protein coding genes, such as
RELA (Additional file 6: Figure S4), perhaps contributing
to regulating their gene expression. To expand on this
analysis, we first examined the function of genes located
nearby novel lncRNAs in the genome by using the com-
putational tool GREAT [20]. GREAT analysis using Gene
Ontology revealed gene functions in the vicinity of novel
lncRNAs were related to immune cell activation and dif-
ferentiation (Fig. 4a). Analysis using a disease-oriented
ontology revealed that novel lncRNA neighborhoods are
enriched with lymphoma or other immune cell malig-
nancy genes (Fig. 4b). This suggests that novel DLBCL
lncRNAs are not randomly located in the genome but
preferentially located near genes with key functions in B
cells and malignant B cells, perhaps contributing to the
regulation of the function and expression of these genes.
To further explore the potential function of novel
lncRNAs we performed a systematic co-expression ana-
lysis with known protein-coding genes. Correlating each
lncRNA expression to known protein coding gene ex-
pression generated sets of significantly co-expressed
(Spearman correlation; FDR <0.2) genes for each novel
lncRNA (Additional file 7). About 88 % of the lncRNAs
showed significant correlation with at least one protein-
coding gene. We performed pathway analysis on the set
of co-expressed protein coding genes for each lncRNA
using Gene Ontology and lymphoid biology gene sets
from the Staudt lab [21]. Overall, 43 % of the lncRNAs
with co-expressed protein coding genes showed enrich-
ment for at least one or more specific functional
(See figure on previous page.)
Fig. 1 De novo transcript discovery identifies 2,632 novel lncRNA in DLBCL tumors. a A well-organized pipeline was used to discover and obtain
candidate lncRNAs. Using aligned 116 tumor and eight normal B cell samples, the transcriptome was reassembled using CuffLinks in de novo
mode. A cohort of the assembled transcripts for each sample was then created using CuffMerge and parsed out for novel unannotated transcripts
using CuffCompare, given a consensus reference of all known annotations from various sources – UCSC, RefSeq, ensemble, and GencodeV17.
Initially we discovered 40,258 unannotated novel transcripts. b Stringent filtering steps applied to the initially discovered novel transcripts to
remove artefactual novel lncRNAs, based on selection of non-coding transcripts using CPAT, transcript length, and exon count. Post these, expression
level filtering (FPKM> 0.1 in two samples or more) across each sample group was performed, respectively. c GENEID coding potential score was used
to validate the coding potential comparing known LncRNAs, novel lncRNAs, and protein-coding genes. The known lncRNA emulate the novel
LncRNAs’ low average coding potential score, while a higher average coding potential score for protein coding genes is observed. d Transcript length
using a density plot was also compared – showing common patterns for known lncRNAs and novel lncRNAs, with protein coding gene, were much
longer in length. e Based on the 2 exon on more cutoff, the bar plot shows all novel lncRNA, similar to known lncRNAs have at least 2 or more exons.
Protein coding has a lot more exons compared to the known and novel lncRNAs. f Bar plot showing, selected lncRNA based on FPKM filtering (FPKM >
0.1 in two or more samples) in DLBCL tumor samples, ordered to show count of selected lncRNAs expressed per tumor sample (n = 116)
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pathways (Additional file 8) such as CD40 upregulation
and CD40 downregulation pathways (Fig. 4c). Reasoning
that the function may in theory be transferred between
co-expressed protein coding genes and lncRNAs, this
means that a bit under half of our novel lncRNAs can be
given at least one putative function. We then specifically
examined correlations between our lncRNAs and ex-
pression of EZH2, a transcriptional repressor, implicated
in tumorgenesis in DLBCL due to frequent mutations
and with known interactions with lncRNAs [22, 23].
Since co-expressed genes are known to be enriched for
physically interacting gene products, we reasoned that
positive correlations might uncover potential EZH2
interaction partners [24, 25] or alternatively lncRNAs
regulated by the same transcriptional mechanisms as
EZH2. Negative correlation might represent EZH2 re-
pressed lncRNAs. We identified 682 lncRNAs to be sig-
nificantly correlated (FDR <0.2) with EZH2, out of
Fig. 2 Many of the novel DLBCL lncRNAs are tumor-specific. a Selected novel lncRNA candidates were quantified for FPKM levels across each
sample group. Filtering based on FPKM cutoff of FPKM >0.1 in at least two samples, in each sample group, respectively, showed 785 lncRNAs
commonly expressed in tumors, normal, and cell lines. Also 763 lncRNA expressed in tumors and cell lines, while 142 lncRNAs expressed in normal and
tumor, with 942 of the lncRNAs expressed uniquely only in tumors. b Number of lncRNAs expressed per sample with each sample group, plotted to
show the expression across each sample group – with normal B cell sample group with higher average number of lncRNA expressed per sample,
followed by tumor sample group and then cell lines. c An example of lncRNAs with exceptionally high expression (> = 10 standard deviation above
mean) in specific tumor samples (out of 45 such lncRNAs) across all tumor samples
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which 251 positively (example shown in Fig. 4d) corre-
lated and 431 negatively correlated (example shown in
Fig. 4e) [26]. In a siRNA knockdown analysis of EZH2 in
four DLBCL cell lines - OCI-Ly7, Farage, SUDHL5, and
WSUDLCL2, 182 of the lncRNAs negatively correlated
with EZH2 were seen as upregulated (log2 fold change
siEZH2/ control >1). This number was significantly
higher than expected by chance according to the hyper-
geometric test (P <0.011), supporting the hypothesis that
many lncRNAs negatively co-expressed with EZH2 may
Fig. 3 Quantifying present isoforms for the novel lncRNAs. a With most lncRNAs being single transcripts, about 35 % of the novel lncRNAs
seemed have isoforms. (Plot axis cutoff, number shows lncRNAs with at least 1 isoform). b Sashimi plot for one of the novel lncRNAs (XLOC_003929)
shows expression and clearly defined slice sites for a novel lncRNA with five isoforms, across three tumor samples. c An IGV browser screenshot shows
the RNA-seq reads aligned to the same novel lncRNA (XLOC_003929) from (b), confirming expression patterns along the splice-site, as per the
detected isoforms
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indeed be repressed by EZH2. Similar analysis with
BCL6 expression across tumors resulted in 323 nega-
tively correlated lncRNAs (FDR <0.2). In a siRNA
knockdown analysis of BCL6 in OCI-LY1 DLBCL cells
[27], 104 of these lncRNAs were also seen to be upregu-
lated (log2 fold change siBCL6/siNT >1) at 24 h time
point BCL6 knockdown, while 48 of them are upregu-
lated (log2 fold change siBCL6/siNT >1) at a 48 h time
point knockdown of BCL6. As with EZH2, these num-
bers were significantly higher than expected by chance
according to the hypergeometric test at 24 h (P <0.031)
and 48 h time points (P <0.032). These negatively corre-
lated lncRNAs are potential novel BCL6 targets since
BCL6 is an obligate repressor [16].
Novel DLBCL lncRNAs are frequently DLBCL subtype
specific and enriched at DLBCL super enhancers
In DLBCL, differentiation block of B cells at different
stages at least partially characterizes its known subtypes -
ABC and GCB [1]. Both subtypes are known to have dis-
tinct prognosis, as a result of known variations in their
gene profiles and association with distinct signaling path-
ways. We first classified 104 tumor samples (Additional
file 9) into either GCB or ABC based on the published
ABC/GCB classic expression based signature [28]. Using
supervised analysis, we sought to discover novel ABC- or
GCB-specific lncRNAs and identified 465 such lncRNAs
(FDR <0.05; see Methods; 1,934 lncRNAs were obtained
using FDR <0.2). Heatmap plots with unsupervised
clustering (using hclust function in R) of the primary
tumor samples, confirmed the pattern of subtype specific
gene expression for these 465 significantly differentially
expressed lncRNAs across ABC and GCB (Fig. 5a).
Figure 5b illustrates examples of GCB and ABC-specific
lncRNAs. This analysis confirms that many of our
lncRNAs are not random and behave similarly to protein
coding genes. Additionally, a similar analysis performed
using 7,806 out of the 15,851 known lncRNAs (Broad in-
stitute Human Catalog, GENCODE V17) expressed >0.1
FPKM in at least two or more tumor samples, identified
subtype specific known lncRNAs, with 891 (FDR <0.05;
2,088 lncRNAs were obtained using FDR <0.2) signifi-
cantly differentially expressed and clustering (unsuper-
vised clustering using hclust method in R; method ward)
across the two subtypes (Additional file 10: Figure S5).
We also analyzed the correlation between novel
lncRNAs and 283 DLBCL super-enhancers [29]. We
found that 81 super-enhancers overlapped with our
novel lncRNAs. Upon shuffling the enhancer locations
1,000 times we found that only 17 shuffled super en-
hancers on average overlap with lncRNAs (P <0.001).
We conclude that DLBCL super-enhancers are enriched
in novel lncRNAs, as illustrated in the BCL6 upstream
region (Additional file 11: Figure S6). We speculate that
the open chromatin at these super-enhancers perhaps
combined with cryptic promoters may facilitate lncRNA
expression. We note that lncRNAs as defined here are
different from shorter non-polyadenylated and non-
spliced enhancer RNAs (eRNA) [30].
Novel lncRNAs overlap with key histone marks,
transcriptional regulators, and independently derived
transcripts
To provide further support for the existence and func-
tional role of our novel lncRNAs, we examined whether
these the genomic loci of these novel lncRNAs were
enriched of specific histone marks or bound by certain
transcription factors.
H3K4me3 ChIP-seq data in DLBCL cell line OCI-LY1
(publicly available GEO data: GSE29282) [18] together
with the 2,632 lncRNAs were used to further validate
our lncRNAs. We created a transcription start site (TSS)
plot (Fig. 6a) that reflects average H3K4me3 read coverage
across the genome at and around the TSS of novel
lncRNAs. Such plots, when determined from well-
annotated protein coding genes (hg19 RefSeq) (Additional
file 12: Figure S7), show a nucleosome-free region slightly
upstream of the TSS and +1 nucleosome downstream.
The TSS plot at the novel lncRNAs show a similar pattern,
thus supporting the inferred TSS location for our novel
lncRNAs and their validity as novel genes.
We also analyzed known lymphoma oncogenes -
NFkB [31] and STAT3 [32] - to find out if their expres-
sion could be regulated by these oncogenes. Since we do
not have NFkB binding data in lymphoma cells, we used
NFkB binding data in lymphoblastoid cells from EN-
CODE [33] instead. We found that the overlap between
our novel lncRNAs and NFkB ChIP-seq peaks (6,959
peaks) was limited but nonetheless existent (7 % peaks).
For STAT3 ChIP-Seq peaks (6,256 peaks) in DLBCL cell
(See figure on previous page.)
Fig. 4 Integrative analysis reveals potential functions of DLBCL specific novel LncRNAs. a Biological processes GO ontology from GREAT, shows
enrichment for various B cell and lymphoma-related pathways based on the nearby genes possibly regulated by the novel lncRNA. b Disease
ontology from GREAT also shows lymphoma-specific disease pathways enriched based on gene in proximity to the novel lncRNAs. c Example of
some lncRNAs with significant P values (Boniferroni, P value <0.05) which possibly regulate the functional pathways related to CD40- shown here
with number of co-expressed protein coding genes for each, the related CD40-functional pathway, the subset of those co-expressed genes
present in the pathway gene set. d Example of a significantly positively correlated lncRNA expression with EZH2 expression across DLBCL tumor
samples. e Example of significantly negatively correlated lncRNA expression with EZH2 expression across DLBCL tumor samples
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line OCI-LY7 (publicly available GEO data: GSE50723)
[20], we also found a small fraction of overlap (3 % out
of the 2632 lncRNAs) with the novel lncRNAs.
To further validate our novel lncRNAs, we looked for
overlap between them and long read (PacBio)-derived
transcripts from lymphoblastoid cells [34]. We found
that 10 % of our novel lncRNAs overlapped with the
PacBio data. Most importantly, visualization showed
clear conservation of the overlapping novel lncRNA
structures in these independently derived samples
(Fig. 6b).
Role of transposable elements in lncRNAs
Repetitive DNA sequences, also known as transposable
elements (TE) are abundantly found in the genome. It
has been reported by others that several lncRNAs con-
tain transposable elements, for example, PCAT1 [35,
36]. In some cases, it is thought that TE may mediate
Fig. 5 Novel DLBCL lncRNAs are frequently DLBCL subtype specific. a Heatmap showing overall differential expression for the significantly
differentially expressed lncRNAs (n = 465) across 104 ABC and GCB classified samples, respectively. b Comparing novel lncRNA with significantly
(adjusted P value <0.05) higher mean expression in ABC subtype classified tumor samples (n = 35 out of 104 classified samples) c Novel LncRNA
with significantly (adjusted P value <0.05) higher mean expression in GCB subtype classified tumor samples (n = 69 out of 104 classified samples)
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the function of lncRNAs, allowing them to recognize
and bind to target mRNAs containing TEs [37]. When
we examined the exonic overlap between our lncRNAs
and TEs using BEDtools [38] intersect, we found that up
to 93 % of the lncRNAs overlap with TEs by 1 bp or
more. Increasing the overlap threshold to 10 bp we
found similar TE overlap of approximately 90 %. Overall,
nearly half (53 %) of the lncRNA transcript sequences
are TE-derived, that is 53 % of lncRNA nucleotides ori-
ginate from TEs (Fig. 7a; see Methods). This fraction is
much lower with protein-coding genes but more com-
parable to known lncRNAs (Fig. 7a). We further
investigated the nature of the overlap and found that the
last exon of novel lncRNAs vastly more frequently over-
laps with TEs than the first exon (P <2.2e-16, chi-square
test; Fig. 7b). Overall, these results hold for known
lncRNAs albeit to a lower extent. We find that approxi-
mately 82 % of known lncRNAs (from Broad institute
Human Catalog, GENCODE V17) overlap with TEs
(using BEDtools intersect) and approximately 30 % of
whose sequence is derived from TEs (using RepeatMas-
ker; Fig. 7a). Likewise we observe that in known
lncRNAs, the last exon overlaps more frequently with
TEs than the first exon (P <2.2e-16; chi-square test)
a
b
Fig. 6 Novel lncRNAs overlap with key histone marks, transcriptional regulators, and independently derived transcripts. a Transcription Start Site
plot showing average H3K4me3 read coverage across the entire genome at and around the TSS of the novel lncRNAs, with a nucleosome-free
region slightly upstream of the TSS and a +1 nucleosome downstream. b IGV screenshot showing a well conserved overlapping lncRNA in the
independent PacBio-derived transcript from (c)
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(Additional file 13: Figure S8), even if overall first and
last exon overlap with TEs is lower in known lncRNAs
compared to our novel lncRNAs. Last exon overlap with
TEs is a previously unappreciated feature of lncRNAs
and is compatible with lncRNA using cryptic polyadeny-
lation signals [38] contained within TEs [39] and may in
fact contribute to the biogenesis of novel lncRNAs (in-
cluding disease-specific ones) on a scale that was not yet
appreciated.
Cross-species identifies conserved lncRNA transcription
between dog and human lymphomas
With the aim to further affirm the existence of these
DLBCL specific novel lncRNAs, we performed a cross-
species analysis with canine lymphoma samples to assess
conservation of these lncRNA across the same tumor
type in both species. We analyzed dog lymphoma RNA-
seq samples [40] because dogs get lymphomas whose
features are similar to human lymphomas [41]. We rea-
soned that identifying conserved features between human
and dog lymphoma lncRNAs may help underscore the im-
portance of these features. Thirteen dog lymphoma sam-
ples were aligned to the dog genome (CanFam3), put
through de novo transcript assembly and filtered to obtain
multiexonic transcripts, similar to the novel lncRNA pipe-
line we used for human DLBCL analysis. For a uniform
comparison across human and dog genomes, the Liftover
tool was used to convert human novel lncRNAs to the
dog genome coordinates and BEDTools was used to assess
overlap. We found that 244 (9 %) human novel lncRNAs
lifted over to CanFam3 showed at least partial exonic
overlap with dog transcripts, where not the entire tran-
script overlaps but few exons or parts of exons overlap
(using BEDTools intersect with specific bp overlap cutoff
of 10 bp). Interestingly, as exemplified in the case of
lncRNAs near the BCL6 oncogene (Fig. 8), dog lncRNAs
and human lncRNAs tend to be found in the same regions
but are not located at the same exact location and do not
necessarily overlap in terms of structure. That we none-
theless found 244 lncRNAs with at least one overlapping,
sequence-similar exon is important since it is possible
that novel DLBCL-specific lncRNA may represent
interest targets for antisense pharmacology [9 ] and
may enable cross-species clinical trials of such anti-
sense oligonucleotides.
Mutation analysis suggests that mutations in lncRNAs
stabilize their structure
We wondered whether mutation analysis of lncRNAs
would reveal lncRNA mutations and whether it would
be possible to understand what these mutations may do
functionally. Using VarScan [42] with default parame-
ters, we performed a systematic mutation analysis of our
lncRNAs and found a total of 9,713 novel candidate
Fig. 7 Role of TEs in lncRNAs. a Sequence-based TE content was calculated using RepeatMasker in known lncRNAs, novel lncRNAs, and protein-
coding genes. Novel lncRNAs (53 % TE content), similar to known lncRNAs (30 % TE content) showed higher TE content compared to protein
coding genes (6 % TE content). b Varied novel lncRNA exons and TE overlap patterns were noted, with a higher chance of a last exon overlap
with a TE
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mutations within exonic regions of these lncRNAs after
filtering out all known polymorphisms from dbSNP (re-
lease 142). Upon further filtering of variants found in
our eight normal B cell RNA-seq samples (analyzed with
the same parameters), we were left with 9,447 tumor-
specific candidate mutations. This analysis suggests that
lncRNAs may harbor frequent mutations (SNV) in
DLBCL. We note, however, that this analysis is limited
by the absence of matched normal comparators for our
RNA-seq cases and that it cannot be excluded that some
of these SNVs are in fact rare germline SNPs or sequen-
cing errors. Out of these novel 9,447 SNVs, about 60 %
of them re-occurred in at least 10 % of the tumor sam-
ples. A hotspot analysis, to find mutation frequency over
a window of 100 bp, revealed 1,805 mutation hotspots
with at least six or more mutations (either from inde-
pendent samples or from the same sample). This
suggests significant clustering of mutations in novel
lncRNAs. We then wondered whether putative muta-
tions in these lncRNAs would stabilize or destabilize the
lncRNA secondary structure, leading to dysregulation of
possible target genes and pathways. A Minimum Free
Energy Score (MFE) was calculated for the native
lncRNA sequence and the corresponding lncRNA se-
quence with one or more novel mutations using the tool
RNAfold [43] and difference in MFE was calculated for
each lncRNA. While many mutations did not seem to
show any change in the MFE post mutation, a shift was
evident toward stabilization of secondary RNA struc-
tures due to the positive difference in the MFEs of the
original lncRNA and the mutated lncRNA (Fig. 9a). As a
control, we performed the same analysis using 9,447
randomly selected dbSNP variants (common polymor-
phisms) detected in our samples in these lncRNAs and
found that indeed the dbSNP variants were less likely to
stabilize lncRNAs than the novel variants (P <2.2e-16;
Wilcoxon test; Fig. 9b). Altogether these results identify
a yet unappreciated potential role for DLBCL mutations
in stabilizing lncRNAs, perhaps helping epigenetic
mechanisms such as those mediated by EZH2 in pro-
moting lymphomagenesis and maintaining the tumor
identity [44]. Figure 9c and d illustrates how slight sta-
bilizing changes in the MFE of a novel lncRNA’s struc-
ture due to the novel mutations correlate with structural
changes between the original and the mutated lncRNAs.
Discussion
In this study, we identified 2,632 novel, multi-exonic
candidate lncRNAs expressed in more than one DLBCL
tumor. We found that a majority of our novel DLBCL
specific lncRNAs seemed to have significant correlations
with known data sets (Additional file 14), which suggests
many of these discovered novel lncRNA potentially hold
regulatory functions in DLBCL. H3K4me3 density
Fig. 8 Cross-species identifies conserved lncRNA transcription between dog and human lymphomas. a Ensembl Dog (Canfam3) GTF show the
homologs of BCL6 and LPP genes, reconstructed dog lymphoma transcriptome, shows traces of human lncRNA overlap with known gene
annotations such as BCL6 and LPP gene as reference, transcripts in between the two show overlap with some of the lifted over human lncRNAs
in Dog genome. About 9 % the human lncRNAs were identified with some overlap in the dog lymphoma transcriptome
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(obtained by ChIPseq in a DLBCL cell line) at and
around the predicted TSS of these lncRNAs shows a
similar pattern compared to known protein coding genes,
indicating their potential roles as active genes. These ana-
lyses provide a strong validation for the potential role and
activity of these lncRNAs in DLBCL tumorgenesis and
possibly tumor maintenance. Gene correlations with
protein-coding genes show a large fraction (>80 %) of
lncRNAs to be significantly co-expressed with at least one
gene, suggesting potential co-regulation of genes not only
nearby but also in the distant genome and their strategic
positioning along these potent co-regulated genes. A sig-
nificant number (43 %) of our lncRNAs show enrichment
for important DLBCL-related functional pathways based
on the co-expressed protein coding genes. Studying some
of these pathways should provide insight on the specific
functions of these lncRNAs and their roles. Some of these
lncRNAs also expressed in cell lines, make them tractable
targets to be studied in future experimental testing, for ex-
ample to identify their tumor driver role or their regula-
tory functions.
In accordance with previous studies, our findings show
lncRNAs to have a significant amount of overlap with
transposable elements, which we hypothesize, may help
define the regulatory functions for some of these novel
lncRNAs. The preferential last exon overlap may also
suggest a role for repeat element in birth of new genes,
perhaps as a result of polyadenylation signals contained
in these repeat sequences.
Finally, while previous studies have identified novel
lncRNAs across specific cell types, to our knowledge, none
have performed a cross species analysis of their lncRNAs
in canine lymphomas. A cross-species reference in dog
lymphomas additionally strengthens our claim for the ex-
istence of lymphoma specific lncRNAs and may facilitate
focused anti-lncRNA therapeutic trials in dogs.
a b
c d
Fig. 9 Mutation analysis suggests that mutations in lncRNAs stabilize their structure. a Difference in MFE (in kcal/mol unit) of native novel lncRNA
sequences and mutated sequence with novel mutations shows a shift towards positive end of the scale, indicating stabilization of the secondary
RNA structure of the lncRNAs by the novel mutations. b As a control, difference in MFE (in kcal/mol unit) of native novel lncRNA sequences and
known dbSNP annotated mutations show a shift towards the negative end of the scale, indicating destabilization of the secondary structure by
the dbSNP mutations. c Secondary structure of the original sequence of a lncRNA using RNAfold. d Secondary structure of the mutated sequence
for lncRNA shown in (c). The slight change in MFE due to the mutations is also projected in the MFE secondary RNA structure, as highlighted
Verma et al. Genome Medicine  (2015) 7:110 Page 15 of 17
Finally, a number of supporting evidences point to a
potential driver role for at least some of our novel
lncRNAs. First we find that several lncRNAs are highly
expressed in only a few tumor samples, reminiscent of
aberrant over-expression due to gene fusions. We dis-
covered many novel mutations in the exonic regions of
these novel lncRNAs and subsequent analysis suggests
that these mutations may frequently stabilize the lncRNAs
secondary structures; this suggests frequent gain of regula-
tory function due to increased lncRNA stability, perhaps
reinforcing epigenetic deregulation linked with lympho-
magenesis [45].
Conclusions
This exhaustive analysis of novel lncRNAs in DLBCL
using RNA-seq from primary tumors, uncovers novel
lncRNAs with our validations suggesting their potential
regulatory roles and functions in DLBCL tumorgenesis.
The cross-species analysis cross-validates the existence
of these lymphoma specific lncRNAs and could poten-
tially serve as a basis for future lymphoma clinical trials
in Dogs. In addition to expanding the DLBCL transcrip-
tome, these lncRNAs also provide abundant source of
new targets for antisense oligonucleotide pharmacology.
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